Clinical Trial: Amniotic Fluid Mesenchymal Stem Cells Developed for Chondrogenic Treatment (AFCC) Injection in Elderly Knee Osteoarthritis Patients

U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06386679) titled 'Amniotic Fluid Mesenchymal Stem Cells Developed for Chondrogenic Treatment (AFCC) Injection in Elderly Knee Osteoarthritis Patients' on March 29.

Brief Summary: Amniotic fluid mesenchymal stem cells developed for chondrogenic treatment (AFCC) are used to treat elderly patients suffering from knee osteoarthritis (OA). The injection reduces inflammation and promotes the recovery of knee function, leading to an improved quality of life.

Study Type: Interventional

Condition: Knee Osteoarthritis

Intervention: Biological: allogenic amniotic fluid mesenchymal stem cell

Intra-articular AFCC injection will be given for single knee for e...